Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Mercaptopurine Anhydrous. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KA | P42356 | 2/20 | 0.33 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.33 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.33 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
| ▸ | XDH | P47989 | 1/20 | 0.33 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.33 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.31 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
| ▸ | HBB | P68871 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mercaptopurine Anhydrous SCHEMBL5144252 | 0.98 | PI4KA (0.32) | PI4KAPI4K2BPI4K2API4KBLMNA | |
| Mercaptopurine Anhydrous SCHEMBL734087 | 0.98 | PI4KA (0.32) | PI4KAPI4K2BPI4K2API4KBLMNA | |
| Mercaptopurine Anhydrous SCHEMBL7199288 | 0.84 | — | — | |
| Mercaptopurine Anhydrous SCHEMBL12476114 | 0.83 | ALDH1A1 (0.62) | PI4KAPI4K2BPI4K2API4KBLMNA | |
| Mercaptopurine Anhydrous SCHEMBL18317326 | 0.77 | LMNA (0.51) | LMNAALDH1A1HBBSMN1; SMN2 | |
| Adenine SCHEMBL3413247 | 0.74 | PI4KA (0.48) | PI4KAPI4K2BPI4K2API4KBLMNA | |
| Adenine SCHEMBL3416954 | 0.74 | PI4KA (0.48) | PI4KAPI4K2BPI4K2API4KBLMNA | |
| SCHEMBL10285464 | 0.74 | PI4KA (0.34) | PI4KAPI4K2BPI4K2API4KBLMNA | |
| Adenine SCHEMBL8110 | 0.74 | PI4KA (0.48) | PI4KAPI4K2BPI4K2API4KBLMNA | |
| Adenine SCHEMBL3414603 | 0.74 | PI4KA (0.48) | PI4KAPI4K2BPI4K2API4KBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 98977 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4746876-A1 | UDP-GLUCOSE CERAMIDE GLUCOSYLTRANSFERASE SYNTHASE (UGCG) INHIBITORS IN THE TREATMENT OF CANCER | Katholieke Universiteit Leuven (BE) | 2026-05-27 | — | — | EP | claimed |
| EP-4748859-A2 | CHEMICALLY AND PHOTOCHEMICALLY INITIATED CELL MEMBRANE BLEBBING TO INDUCE CELL VESICLE PRODUCTION, MODIFICATIONS THEREOF, AND USES THEREOF | The Regents of the University of California (US) | 2026-05-27 | — | — | EP | claimed |
| CN-116209439-B | Cereblon protein modulators | Saint Jude Children's Research Hospital Ltd. (US) | 2026-05-26 | — | — | CN | claimed |
| US-20260138973-A1 | SUBSTITUTED PYRIDINES FOR USE IN TREATING OR PREVENTING INFLAMMATORY DISEASES OR DISEASES ASSOCIATED WITH AN UNDESIRABLE IMMUNE RESPONSE | SITRYX THERAPEUTICS LTD (GB) | 2026-05-21 | — | — | US | claimed |
| US-20260137650-A1 | MODULATORS OF RAR RELATED ORPHAN RECEPTORS (RORs) | 11949098 CANADA INC (CA) | 2026-05-21 | — | — | US | claimed |
| US-20260137680-A1 | NOVEL COMPOUNDS | SITRYX THERAPEUTICS LTD (GB) | 2026-05-21 | — | — | US | claimed |
| WO-2026106497-A2 | FUNCTIONALIZED CIRCULAR RNA AND METHODS AND INTERMEDIATES FOR THEIR PRODUCTION | SIEĆ BADAWCZA ŁUKASIEWICZ – PORT POLSKI OSRODEK ROZWOJU TECHNOLOGII (PL) | 2026-05-21 | — | — | WO | claimed |
| EP-4743490-A1 | HUMANIZED ANTI-CD7 ANTIBODY | Christian-Albrechts-Universität zu Kiel (DE) | 2026-05-20 | — | — | EP | claimed |
| WO-2026101236-A1 | PEPTIDES SPECIFICALLY BINDING TO CCR8, AND USE THEREOF | 경희대학교 산학협력단 | 2026-05-15 | — | — | WO | claimed |
| WO-2026099502-A1 | NOVEL DRUG CONJUGATES FOR TESTING CELLULAR DRUG UPTAKE | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 2026-05-15 | — | — | WO | claimed |
| EP-0009154-B1 | COMPLEXES OF 9-HYDROXYALKYL-PURINES, PROCESSES FOR PREPARING THEM AND THERAPEUTICAL COMPOSITIONS CONTAINING THE COMPLEXES AS ACTIVE INGREDIENTS | Newport Pharmaceuticals International, Inc. (US) | 1982-12-08 | — | — | EP | claimed |
| EP-0038541-A1 | Novel prodrugs of biologically active agents containing mercapto groups, process for preparing and therapeutically effective composition containing the same | MERCK & CO. INC. (US) | 1981-10-28 | — | — | EP | claimed |
| EP-0036138-A2 | Composition of matter for topical application comprising a bio-affecting agent and N,N-diethyl-m-toluamide | MERCK & CO. INC. (US) | 1981-09-23 | — | — | EP | claimed |
| US-4291024-A | ANTICANCER AGENTS | UNIVERSITY OF RHODE ISLAND | 1981-09-22 | — | — | US | claimed |
| EP-0033341-A1 | CYTOTOXIC NUCLEOSIDE-CORTICOSTEROID PHOSPHODIESTERS | Research Corporation (US) | 1981-08-12 | — | — | EP | claimed |
| US-4283394-A | ANTICARCINOGENIC AGENTS | RESEARCH CORPORATION (US) | 1981-08-11 | — | — | US | claimed |
| WO-1981000410-A1 | CYTOTOXIC NUCLEOSIDE-CORTICOSTEROID PHOSPHODIESTERS | RESEARCH CORP (US) | 1981-02-19 | — | — | WO | claimed |
| EP-0007206-A1 | Phenethanolamines, their formulations, preparation and use | ELI LILLY AND COMPANY (US) | 1980-01-23 | — | — | EP | claimed |
| US-4147767-A | CROSSLINKED WITH FORMALDEHYDE OR GLUTARALDEHYDE | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1979-04-03 | — | — | US | claimed |
| US-4108804-A | Process for preparation of chromatography solid supports comprising a nucleic acid base-epoxy group containing porous gel | SEITA TORU | 1978-08-22 | — | — | US | claimed |